Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Greipp

Showing results (131-140 of 178) with videos related to

Pageof 18
Sort By:
Hematologic Pathology|January 1, 1991
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling indexP Beauregard, T E Witzig, P J Kurtin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1994
CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell lineJ J Westendorf, G J Ahmann, R J Armitage, et al.
Journal of Immunological Methods|October 23, 1986
S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatmentN J Gonchoroff, J A Katzmann, R M Currie, et al.
American Journal of Hematology|August 10, 1999
Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486M C Trendle, T Leong, R A Kyle, et al.
Cancer Research|November 1, 1993
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implicationsD F Jelinek, G J Ahmann, P R Greipp, et al.
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Leukemia & Lymphoma|May 9, 2001
Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosisR Fonseca, S V Rajkumar, G J Ahmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
British Journal of Haematology|December 19, 1998
Chromosomal abnormalities in systemic amyloidosisR Fonseca, G J Ahmann, S M Jalal, et al.
Bone Marrow Transplantation|August 5, 2000
Delayed stem cell transplantation for the management of relapsed or refractory multiple myelomaM A Gertz, M Q Lacy, D J Inwards, et al.
Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
Hematologic Pathology|January 1, 1991
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling indexP Beauregard, T E Witzig, P J Kurtin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1994
CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell lineJ J Westendorf, G J Ahmann, R J Armitage, et al.
Journal of Immunological Methods|October 23, 1986
S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatmentN J Gonchoroff, J A Katzmann, R M Currie, et al.
American Journal of Hematology|August 10, 1999
Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486M C Trendle, T Leong, R A Kyle, et al.
Cancer Research|November 1, 1993
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implicationsD F Jelinek, G J Ahmann, P R Greipp, et al.
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Leukemia & Lymphoma|May 9, 2001
Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosisR Fonseca, S V Rajkumar, G J Ahmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
British Journal of Haematology|December 19, 1998
Chromosomal abnormalities in systemic amyloidosisR Fonseca, G J Ahmann, S M Jalal, et al.
Bone Marrow Transplantation|August 5, 2000
Delayed stem cell transplantation for the management of relapsed or refractory multiple myelomaM A Gertz, M Q Lacy, D J Inwards, et al.
Pageof 18